Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Innovative Chronic Pain Treatment Receives IP Protection in India's $55 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ -- Innocan Pharma ...

Reports Q4 revenue $$227.00M, consensus $140.95M.”With the recent launch of our first independent medicine, TRYNGOLZA for familial ...

The Company’s 2025 financial guidance reflects its evolution to a fully integrated commercial-stage biotechnology company independently ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Discover key insights from Basilea Pharmaceutica AG's Q4 2024 earnings call. Learn about robust revenue growth, FDA approvals, and pipeline advancements.

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

Welcome to Adeia's Fourth Quarter 2024 Earnings Conference Call. During today’s presentation, all parties will be in listen-only mode. Following the presentation the call will be open for questions. I ...

Q4 2024 Management View CEO Herriot Tabuteau highlighted that Axsome has expanded its CNS portfolio to include three commercial products and three late-stage pipeline candidates. The company aims to ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...